Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study.

Babu, K Govind; Prabhash, Kumar; Vaid, Ashok K; Sirohi, Bhawna; Diwakar, Ravi B; Rao, Raghunadha; Kar, Madhuchanda; Malhotra, Hemant; Nag, Shona; Goswami, Chanchal; Raina, Vinod; Mohan, Ravi

Babu, K Govind; Prabhash, Kumar; Vaid, Ashok K; Sirohi, Bhawna; Diwakar, Ravi B; Rao, Raghunadha; Kar, Madhuchanda; Malhotra, Hemant; Nag, Shona; Goswami, Chanchal; Raina, Vinod; Mohan, Ravi.

Afiliação

Babu KG; Kidwai Memorial Institute of Oncology, Bangalore, India.
Prabhash K; Tata Memorial Hospital, Mumbai, India.
Vaid AK; Artemis Health Institute, Delhi, India.
Sirohi B; Artemis Health Institute, Delhi, India.
Diwakar RB; Bangalore Institute of Oncology, Bangalore, India.
Rao R; Nizam Institute of Medical Sciences, Hyderabad, India.
Kar M; B R Singh Hospital, Kolkata, India.
Malhotra H; Birla Cancer Centre, Jaipur, India.
Nag S; Jehangir Hospital, Pune, India.
Goswami C; B P Poddar Hospital and Medical Research Ltd, Kolkata, India.
Raina V; Institute Rotary Cancer Hospital, New Delhi, India.
Mohan R; King George Hospital, Visakhapatnam, India, India.

Onco Targets Ther ; 7: 1051-60, 2014.

Article em En | MEDLINE | ID: mdl-24966687

Palavras-chave

carboplatin; docetaxel; epidermal growth factor receptor; nimotuzumab; non-small cell lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Onco Targets Ther Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google